echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > On-site negotiations on the national medical insurance drug catalogue in 2022 begin! What are the concerns?

    On-site negotiations on the national medical insurance drug catalogue in 2022 begin! What are the concerns?

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On January 5, the on-site negotiation of the 2022 National Medical Insurance Drug Catalogue officially began, which attracted the attention
    of the pharmaceutical industry and the general patient group.

    According to the list of drugs that passed the preliminary examination of the "National Talks", a total of 343 drugs out of 490 declared drugs of the National Talks in 2022 passed the preliminary examination
    Among them, there are 198 drugs outside the list, including 144 exclusive varieties of Western medicines and 14 exclusive varieties of proprietary Chinese medicines
    These drugs cover tumors, rare diseases and other therapeutic drugs

    Price is the focus of the industry, many securities companies believe that the price adjustment of innovative drugs in this medical insurance negotiation price will be relatively moderate, among which analysts at Essence Securities predict that according to the current simple renewal rules, the price reduction of innovative drugs after new indications may be within 44%, which is narrower than the possible average reduction of 50%~60% in renegotiation
    The industry expects that large pharmaceutical companies with high innovation value, excellent clinical effects and cost advantages are expected to stand out in the fierce negotiations and fully share the dividends
    of the medical insurance fund.

    Among the drugs that have attracted much attention in this round of negotiations, there are a number of blockbuster new drugs
    that have been negotiated for the first time.
    For example, Akeso's "Cardunilimab", which is the first domestic bispecific antibody and the world's first approved PD-1-based bispecific antibody, was approved for marketing in China on June 29, 2022, for patients with relapsed or metastatic cervical cancer
    who have previously failed platinum-containing chemotherapy 。 It is reported that the current price of the drug is 13220 yuan / 125 mg / bottle, in order to reduce the burden of patients' drug costs, Akeso Biologics in addition to participating in the medical insurance negotiation, but also revealed that it is actively participating in various national and local medical security systems, and adopting patient rescue programs, the annual treatment cost is not higher than 198,000 yuan

    PD-1/PD-L1 drugs are also a major attraction, it is reported that a total of 6 domestic PD-1 monoclonal antibody products participated in this medical insurance negotiation, of which the PD-1 monoclonal antibody products of Hengrui Pharmaceutical, BeiGene, Innovent Biologics, Junshi Biologics and other 4 domestic pharmaceutical companies in medical insurance are new indication negotiations, while Henlius, Corning Jerry/Sidi/Simcere Pharmaceutical and other pharmaceutical companies PD-L1 monoclonal antibody products are the first to participate in medical insurance negotiations

    For example, in the field of rare disease drugs, which have always been expensive, there are a total of 19 rare disease drugs in this year's preliminary review list, including spinal muscular atrophy (SMA) oral drug rispram oral solution powder, Castleman disease treatment drug stuximab, treatment drug ranarisumab injection, Gaucher disease treatment drug injection veraside A injection and other high-value drugs for rare diseases

    Among them, the rare disease Castleman disease is a rare disease in the field of blood, which was included in China's "First Rare Disease List"
    in 2018.
    Due to the lack of unified and clear diagnostic criteria, the symptoms are diverse, and differential diagnosis is difficult, and patients with this disease have faced more severe survival challenges
    In December 2021, stuximab was approved by the State Food and Drug Administration for the treatment of multicenter Castleman disease adult patients with human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative adulthood, and was officially commercialized in China in July 2022.

    In addition, the domestic CAR-T relmacel injection with an annual treatment cost of millions is also on
    the list of this negotiation.
    The product was approved for marketing on September 3, 2021 at a price of 1.
    29 million per unit for the treatment of relapsed or refractory large B-cell lymphoma in adult patients after two or more lines of systemic therapy and for the treatment of adult refractory or relapsed follicular lymphoma
    within 24 months after two or more lines of systemic therapy.

    It is understood that since the establishment of the National Medical Insurance Administration, the medical insurance drug list has been adjusted for four consecutive years, a total of 507 new drugs and good drugs have been included, 391 drugs with inaccurate efficacy have been transferred, the total number of drugs in the current version of the medical insurance catalogue has increased to 2860, and the average price of drugs included in medical insurance through negotiation has been reduced by about 50%-60%, effectively reducing the burden
    on patients.
    What new drugs and good drugs will be included in this medical insurance negotiation? It's worth waiting and seeing!
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.